Using fat-derived stem cells to treat primary progressive multiple sclerosis
Official title: Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis: an Open-label Phase I Clinical Trial.
Run by Rennes University Hospital · NCT06592703 · Data updated 2026-11-12
This study is testing if injections of fat-derived stem cells can help people with primary progressive multiple sclerosis feel better and slow down their disease.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Rennes University Hospital Academic / other |
| Locations | 2 sites (Créteil and 1 other locations) |
| Status | Recruiting |
| Started | March 6, 2025 |
| Main results expected | December 2029 |
| Study ends | December 2029 |
| Registry record updated | January 5, 2026 |
| Trial ID | NCT06592703 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 to 55 with a confirmed diagnosis of primary progressive multiple sclerosis and specific disability criteria.
✕Probably not a fit
Patients with recent inflammatory activity or those currently on disease-modifying drugs may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the safety and potential effectiveness of repeated injections of allogenic adipose tissue-derived mesenchymal stromal cells (ASCs) in patients with primary progressive multiple sclerosis (PPMS). The approach involves administering three intrathecal injections of ASCs every three months, with the hypothesis that this treatment can slow disease progression. The study will begin by establishing a bank of ASCs from healthy donors, followed by screening and enrolling eligible PPMS patients at Rennes University Hospital. Participants will be monitored for one year after receiving the injections.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option to slow the progression of primary progressive multiple sclerosis.
How similar studies have gone: While autologous stem cell therapies have been explored in multiple sclerosis, the use of allogenic adipose-derived stem cells in this context is novel and has not been previously tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with Primary Progressive MS according to the criteria of Mc Donald 2017 (Thompson et al Lancet neurol, 2017) * Age between 18 and 55 years * EDSS score: 3 to 6 at inclusion * Documented evidence of disability progression independent of relapse activity at any point in time over the 2 years prior to the screening visit * Positive CSF with oligoclonal bands * For women of childbearing potential (WOCBP), effective contraception as per the CFTG recommendations (version 1.1) * Having signed a free, informed and written consent * Affiliated to social security scheme Exclusion Criteria: * Inflammatory activity during the past year (relapses or new T2 MRI lesions) * Disease Modifying Drugs during the past year * Treatment with high dose corticosteroids during the 30 days preceding the inclusion * Contra indication to lumbar puncture/intrathecal infusion: intracranial hypertension, puncture site infections, severe thrombocytopenia (\<50 G/L), anticoagulant or fibrinolytic treatment * Participation in another therapeutic trial in the last 6 months * Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of their liberty, pregnant or breastfeeding women, minors, persons unable to express their consent
Where it's running
-
CHU Rennes
Rennes, France Recruiting -
APHP Henri Mondor
Créteil, France Active not recruiting
Study contacts
- Principal investigator: Laure MICHEL, Pr — Rennes University Hospital
- Study coordinator: Laure MICHEL, Pr
- Email: laure.michel@chu-rennes.fr
- Phone: 0299284321
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treadmill-based virtual reality walking training for MS patients
This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.
-
Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS
This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.
-
REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care
This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.
-
Tolebrutinib in real-world MS care for patients treated by clinicians
This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.
-
Pilates via live video vs. prerecorded videos for people with multiple sclerosis
This study tests whether live, coach-led Pilates sessions through video calls are more beneficial than prerecorded Pilates videos for adults with MS.
-
Cooling During Inpatient Rehab for People with MS
This trial tests whether wearing a cooling vest during intensive training can reduce fatigue and improve walking, strength, balance, and cognition in people with multiple sclerosis during a 3-week inpatient rehab stay.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.